What is the true economic burden of Parkinson’s disease? How does one measure the financial impact of slowly losing the ability to stay independent? Even families with stable incomes or a higher cost of living often find the financial burden gradually building over time. Long-term diseases like Parkinson’s, Alzheimer’s, and ALS change the way people live and work. Changes in routine can force both people with successful careers and everyday individuals living paycheck to paycheck to make adjustments that can greatly affect their finances and living situations. With the addition of medical care, transportation, medications, and the growing need for daily support, the cost of caregiving becomes more expensive while the prices for services continue to rise.
Part of what makes that burden so difficult to manage is that many patients never receive the specialized care their disease requires in the first place. A study titled “Care access and utilization among Medicare beneficiaries living with Parkinson’s disease,” published in npj Parkinson’s Disease in 2023, found that nearly 250,000 people living with Parkinson’s, roughly 40% of all patients that do not see a specialist for their care, despite it being a particularly complex disease to manage. Most explanations point to a straightforward but persistent problem: there are not enough neurologists and movement disorder specialists to go around. According to the American Academy of Neurology, there are an estimated 44,000+ neuroscience professionals associated with the organization, with broader workforce estimates placing the total number of practicing neurologists nationwide at around 17,000–19,000. Of those, only a small percentage practice in rural areas, leaving significant gaps for patients who do not live near a major city or medical center.
Because Parkinson’s disease primarily affects older adults, roughly 90% of patients rely on Medicare coverage, with smaller groups depending on private insurance, Medicaid, Veterans programs, or no stable coverage at all. Yet even with insurance, many families still face mounting out-of-pocket expenses tied to transportation, therapy, caregiving support, home modifications, and long-term care needs that policies do not fully cover. Those uncovered costs are precisely where the financial burden begins to compound.
According to the Parkinson’s Foundation, a report published in March of 2026 by the Michael J. Fox Foundation, the total annual costs for Parkinson’s disease and atypical Parkinsonism reached a staggering $82.2 billion in 2024, already surpassing what many researchers had projected wouldn’t happen until 2037. Of that total, $23.8 billion comes from direct medical expenses like hospitalizations and medications. The larger share, $58.4 billion, comes from indirect costs, including lost income, disability expenses, and unpaid caregiving, according to the report.
At the individual level, that $82.2 billion translates to roughly $82,000 per patient per year, or approximately $23,800 in direct medical costs like hospitalizations, medications, and outpatient care, another $58,400 in indirect and non-medical costs including lost income, disability, and unpaid caregiving, and an additional $8,300 representing what family caregivers lose in earnings alone. According to the Parkinson’s Foundation, the $82,200 per-person number actually understates the household impact, because more than 20% of care partners reduced their hours or retired early, and 34% canceled or missed their own routine health care visits due to the costs of treatment or just trying to live each day.
The findings point to staggering numbers of how Parkinson’s disease and other neurodegenerative diseases have such a financial impact on individuals and families alike, but cold, hard numbers don’t tell the full story. Countless stories all across the world are untold about couples, families, and individual stories of how the disease can ruin lives.
According to a story published on Parkinson’s Disease.net, an art teacher in her forties had been the primary breadwinner for her family for more than two decades when her husband’s Parkinson’s diagnosis finally came, though the first signs had appeared nearly sixteen years earlier, as a tremor in his pinky finger that doctors initially dismissed as essential tremor. By the time the correct diagnosis arrived, she had already quietly reorganized her life around it.
Her husband, a saxophonist who had once commanded a room on stage, channeled his remaining independence into a recording studio, a career that allowed him to work alone and keep his illness hidden from the outside world. She taught during the day, managed the household, raised two sons, one with autism and one with ADHD, and absorbed the financial weight of the family while the studio struggled to break even. It eventually closed. The loss of income and the loss of purpose arrived at the same time.
What followed was not a gradual financial slide but a medical crisis that reshaped everything. Her husband began experiencing Parkinson’s psychosis — a recognized but widely underappreciated non-motor symptom of the disease — waking at 4 am in states of paranoid delusion, requiring emergency intervention, eventually hospitalization. She attended every neurologist appointment, researched every medication change, and filed a peace order to get him the psychiatric care he had refused to seek. He stopped taking his psychosis medication without telling her.
So, she made the decision to divorce him.
Stories like hers rarely surface in cost reports or policy briefs. Yet the sixteen years of financial strain she carried, the career she held onto while managing his care, the childhood she tried to protect for her two sons, that is precisely the kind of loss the numbers are attempting to capture. The $58,400 in annual indirect costs per patient is not an abstract figure. It is a life, measured in what was quietly given up, with no one coming out a winner, except Parkinson’s. Stories like these are real, not something played out on television, even though shows like Shrinking starring Harrison Ford put a lighter spin on the realities of living with Parkinson’s.
This article was not written to solicit pity, and it was not written for those who would use someone else’s hardship as a measuring stick for their own composure. It was written because these stories exist by the millions, largely in private, some in public, like Michael J. Fox, Ozzy Osbourne, Alan Alda, and Muhammad Ali. The people living them deserve to be seen accurately, not sentimentally, and not dismissively. Parkinson’s and other neurodegenerative diseases are going to get more expensive as the years progress because the cost of care, like everything else, is going up. 25.2 million people are projected to get the disease. There’s a good chance that maybe even someone you know will get the disease as they get older.
These reasons, and more, are why the push for funding, both private and by the government, is so important. The cost of research, daily care, medications, experimental treatments and activities to keep people active so to slow disease progression mount up over time.. The report published by the Michael J. Fox Foundation also says that funding matters before a diagnosis is ever made. On average, patients incur more than $10,000 in additional medical expenses in the year prior to receiving a Parkinson’s diagnosis — money spent chasing symptoms that were not yet understood, through specialists who may have been looking for something else entirely. Earlier and more accurate diagnostic tools, made possible through research investment, could eliminate much of that cost and, more importantly, buy patients the time that early intervention requires.
Perhaps the most striking case for increased funding is the math itself. The federal government currently spends more than $25 billion annually caring for people with Parkinson’s through Medicare, Medicaid, and disability programs, yet they invest less than one percent of that figure in research aimed at finding better treatments or a cure. Closing that gap is not just a matter of compassion, it is a matter of long-term fiscal responsibility.
With nearly 90,000 new diagnoses every year and costs already projected to exceed $112 billion annually by 2045, the window to get ahead of this disease is narrowing. What is spent on research and proactive care today is a fraction of what will be required to manage a population of patients whose needs were never addressed early enough. While there are some paid caregivers through insurance or private companies out there, most people do it because they want to, or have to, or it just needs to be done because there isn’t anyone else to do it.
Fundraising and caregiving are all wrapped up into one; it takes one to help do the other, like the chicken and the egg. While you may not see those funds directly, organizations like MJFF, the APDA, and the Parkinson’s Foundation give millions of dollars to research and other supportive groups that funnel down to help supplement costs to help patients. Not to mention, there are smaller organizations in cities everywhere across the U.S. and more across the globe that can be found here
For many families, friends, and strangers, advocacy is not a separate activity from caregiving; it is an extension of who we are as humans. Raising money for research, showing up to promote awareness, and pushing our legislators for action to help fund a cure, these are not things people do instead of caring for someone with Parkinson’s. They are things people do because of it. The motivation behind it is not abstract. It is sitting in the next room.
Image by Chris Denny and ChatGPT
